Borgonovo E, De Cristofaro J, Aletti F, Pedica F, D'Alessio A. Edoxaban-Induced Vanishing Bile Duct Syndrome: A Case Report With Review of the Literature.
Cureus 2024;
16:e68071. [PMID:
39347284 PMCID:
PMC11437016 DOI:
10.7759/cureus.68071]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/12/2024] [Indexed: 10/01/2024] Open
Abstract
Edoxaban is an oral, highly selective, direct factor X-inhibitor approved by the European Medical Agency for the prevention of stroke in non-valvular atrial fibrillation. Edoxaban is contraindicated in patients with severe hepatic insufficiency and, among adverse effects, serum bilirubin level and gamma-glutamyl transpeptidase elevation are described as common events. We report the case of an 82-year-old man with hepatocellular carcinoma who developed a fatal vanishing bile duct syndrome (VBDS) a few weeks after the administration of edoxaban for non-valvular atrial fibrillation. To the best of our knowledge, this is the first report to describe a case of acute VBDS possibly related to edoxaban.
Collapse